We are live on
!
Find out more
RI
RTW Investments Portfolio holdings
AUM
$10B
1-Year Est. Return
135.35%
This Fund
S&P 500
This Quarter
Est. Return
+2.84%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$293M
AUM Growth
+$17.2M
(+6.3%)
Cap. Flow
+$24.2M
Cap. Flow
% of AUM
8.27%
Top 10 Holdings %
Top 10 Hldgs %
72.5%
Holding
39
New
5
Increased
13
Reduced
10
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$16.9M |
| 2 |
SPDR Gold Trust
GLD
|
+$9.99M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$7.07M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$5.76M |
| 5 |
VIVE
VIVEVE MED INC
VIVE
|
+$3.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$7.93M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$4.74M |
| 3 |
Omeros
OMER
|
+$4.49M |
| 4 |
KITE
Kite Pharma, Inc.
KITE
|
+$2.85M |
| 5 |
Lipocine
LPCN
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.44% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MASI
26
DELISTED
Masimo
MASI
| $1.36M | 0.46% |
25,900
| – | – |
|
|
AXDX
27
DELISTED
Accelerate Diagnostics
AXDX
| $1.08M | 0.37% |
7,484
-4,234
| -36% | -$568K |
|
|
CYTR
28
DELISTED
CytRx Corp
CYTR
| $1.04M | 0.36% |
77,700
-7,815
| -9% | -$130K |
|
29
PUT
MannKind Corp
MNKD
$1.21B
| $912K | 0.31% |
877
| – | – |
|
|
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $716K | 0.24% |
131,052
-297,405
| -69% | -$4.74M |
|
|
MDRX
31
DELISTED
Veradigm Inc. Common Stock
MDRX
| $610K | 0.21% |
48,000
| – | – |
|
|
TMBR
32
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
| $455K | 0.16% |
47
| – | – |
|
33
Natera
NTRA
$38.3B
| $382K | 0.13% |
31,693
| – | – |
|
|
ALPN
34
DELISTED
Alpine Immune Sciences Inc
ALPN
| $138K | 0.05% |
7,500
| – | – |
|
|
ADAP
35
DELISTED
Adaptimmune Therapeutics
ADAP
| – | – |
-7,691
| Closed | -$63K |
|
36
Berkshire Hathaway Class B
BRK.B
$1.1T
| – | – |
-50
| Closed | -$7K |
|
|
37
Lipocine
LPCN
$17.5M
| – | – |
-14,143
| Closed | -$2.44M |
|
|
NVRO
38
PUT
DELISTED
NEVRO CORP.
NVRO
| – | – |
-142
| Closed | -$36K |
|
Similar funds
HRCM
RA
GI
IIM
ACA
FPAS
VPIM
OIA
RTW Investments's Q2 2016 Portfolio in Review
As of Q2 2016, RTW Investments held 39 positions worth $293M, up 6.3% from $275M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
RTW Investments deployed $24.2M of net new capital in Q2 2016, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was SPDR Gold Trust: 83,000 shares worth $10.5M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $7.93M trimmed.
- RTW Investments's largest Q2 2016 buy was SPDR Gold Trust: 83,000 shares worth $10.5M.
- RTW Investments added most to bluebird bio in Q2 2016, an estimated $16.9M increase.
- RTW Investments's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $7.93M.
- RTW Investments fully exited Lipocine in Q2 2016, selling an estimated $2.44M.
- RTW Investments's ten largest holdings make up 73% of its $293M portfolio in Q2 2016.
- RTW Investments opened 5 new positions and closed 4 in Q2 2016.
- RTW Investments's portfolio value rose 6.3% quarter-over-quarter to $293M.
Based on RTW Investments's 13F filing for Q2 2016, filed 15 Aug 2016.